

All requests for Rituxan (rituximab) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Rituxan (rituximab) Prior Authorization Criteria:

For all requests for Rituxan (rituximab) all of the following criteria must be met:

- Medication must be prescribed by or in consultation with a Hematologist, Oncologist, Immunologist, Ophthalmologist, Neurologist, Dermatologist or Rheumatologist.
- Must have a therapeutic failure, contraindication, or intolerance to the biosimilar agent(s) FDA-approved or medically accepted for the member's diagnosis
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines

Coverage may be provided for oncology indications (not otherwise listed below):

- **Initial Duration of Approval:** as requested with a maximum of 12 months.
- **Reauthorization Criteria:**
 - Documentation of a positive clinical response
- **Reauthorization Duration of Approval:** as requested with a maximum of 12 months

Coverage may be provided with a diagnosis of Rheumatoid Arthritis and the following criteria is met:

- Member must have a history of trial and failure, contraindication, or intolerance of at least 3 months of treatment with methotrexate or another conventional DMARD (cDMARD).
- Member must have a history of trial and failure, contraindication, or intolerance of at least 3 months of treatment with a tumor necrosis factor (TNF) inhibitor
- Medication will be used in combination with Methotrexate (if not contraindicated or member does not have intolerance to methotrexate).
- **Initial Duration of Approval:** 6 months
- **Reauthorization Criteria:**
 - Documentation of a positive clinical response
- **Reauthorization Duration of approval:** 6 months

Coverage may be provided with a diagnosis of Neuromyelitis Optica (NMO) and the following criteria is met:

- Documentation of at least one attack during the last year or with at least two attacks during the last 2 years
- **Initial Duration of Approval:** 1 month
- **Reauthorization Criteria:**
 - Documentation of a positive clinical response
- **Reauthorization Duration of approval:** 6 months

Coverage may be provided with a diagnosis of Relapsing forms of Multiple Sclerosis (relapsing-remitting, secondary-progressive, or progressive-relapsing multiple sclerosis) and the following criteria is met:

- Member must have a medical history of one of the following:
 - One clinical relapse documented (e.g. functional disability, hospitalization, acute steroid therapy, etc.) during the prior year
 - Two relapses within the prior two years
 - A single clinical demyelinating event and 2 or more brain lesions characteristic of MS
- Member must have documented Expanded Disability Status Scale (EDSS) score of 6.5 or lower
- Must provide documentation showing the member has tried and failed another MS treatment for at least 90 days
- The drug will not be given in combination with other disease modifying therapies approved for the treatment of MS
- **Initial Duration of Approval:** 6 months
- **Reauthorization criteria:**
 - Documentation of clinical response defined as:
 - No increase in their Expanded Disability Status Scale (EDSS) score
 - Member did not experience 1 or more relapses
 - Member does not have 2 or more unequivocally new MRI-detected lesions
- **Reauthorization Duration of approval:** 12 months

Coverage may be provided with a diagnosis of Granulomatosis with Polyangiitis (GPA or Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) and the following criteria is met:

- Must be used in combination with glucocorticoids.
- **Initial Duration of Approval:** 1 month
- **Reauthorization Criteria:**
 - Documentation of a positive clinical response
- **Reauthorization Duration of approval:** 1 month

Coverage may be provided with a diagnosis of Pemphigus Vulgaris and the following criteria is met:

- Member must have mucosal involvement and diagnosis confirmed by ONE of the following:
 - Lesional skin or mucosal biopsy for routine hematoxylin and eosin (H&E) staining.
 - A perilesional skin or mucosal biopsy for direct immunofluorescence (DIF)
 - Serum collection for enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (DIF)
- **Initial Duration of Approval:** 1 month
- **Reauthorization Criteria:**
 - Documentation of a positive clinical response
- **Reauthorization Duration of Approval:** 1 month

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-



Updated: 03/2022
DMMA Approved: 04/2022

reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case-by-case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.

**RITUXAN (RITUXIMAB)
PRIOR AUTHORIZATION FORM – PAGE 1 of 2**

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX:** (855) 476-4158
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE:** (844) 325-6251 Mon- Fri 8 am to 7 pm

PROVIDER INFORMATION

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Health Options ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No		Date Medication Initiated:
Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No		

Billing Information

This medication will be billed: <input type="checkbox"/> at a pharmacy OR <input type="checkbox"/> medically, JCODE: _____
Place of Service: <input type="checkbox"/> Hospital <input type="checkbox"/> Provider's office <input type="checkbox"/> Member's home <input type="checkbox"/> Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis:	ICD Code:
Has a biosimilar agent been tried? <input type="checkbox"/> Yes, please list all below <input type="checkbox"/> No	

Rheumatoid Arthritis:

Which of the following have been tried for at least 3 months:

- Methotrexate or another DMARD
 TNF Inhibitor

Will the medication be used in combination with methotrexate? Yes No

Granulomatosis with Polyangiitis (GPA or Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA):

Will the medication be used in combination with glucocorticoids? Yes No

Pemphigus Vulgaris:

How was the diagnosis confirmed? Please check all that apply:

- Lesional skin or mucosal biopsy for routine hematoxylin and eosin (H&E) staining
 A perilesional skin or mucosal biopsy for direct immunofluorescence (DIF)
 Serum collection for enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (DIF)

Neuromyelitis Optica (NMO):

How many attacks has the member experienced: 1 attack within the past year 2 attacks within the past 2 years

Relapsing forms of Multiple Sclerosis:

Which of the following apply?

- One clinical relapse within the past year
 Two relapses within the past two years
 A single clinical demyelinating event and 2 or more brain lesions characteristic of MS

What is the EDSS score? ≤ 6.5 > 6.5

Will this be used in combination with other disease modifying therapies for MS? Yes No

RITUXAN (RITUXIMAB)

PRIOR AUTHORIZATION FORM (CONTINUED) – PAGE 2 OF 2

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX:** (855) 476-4158

If needed, you may call to speak to a Pharmacy Services Representative.

PHONE: (844) 325-6251 Monday through Friday 8 am to 7 pm

MEMBER INFORMATION

Member Name:	DOB:
Health Options ID:	Member weight: Height:

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

REAUTHORIZATION

Has the member experienced an improvement with treatment? Yes No

For relapsing forms of Multiple Sclerosis, has the member experienced any of the following?

- Increase in EDSS score Yes No
- 1 or more relapses Yes No
- 2 or more unequivocally new MRI-detected lesions Yes No

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature

Date

--	--



Updated: 03/2022
DMMA Approved: 04/2022



Updated: 03/2022
DMMA Approved: 04/2022